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ABSTRACT (205 words)   1 
Cost-effectiveness models that present results in terms of a cost per quality-adjusted life-year 2 
(QALY) for health technologies are used to inform policy decisions in many parts of the world.  3 
Health state utilities (HSU) are required to calculate the QALYs.  Even where clinical studies 4 
assessing the effectiveness of the health technologies collect HSUs to populate the cost-5 
effectiveness model, which rarely happens, analysts generally need to identify at least some 6 
additional HSUs from alternative sources.  When possible, these would be identified by a 7 
systematic review of the literature, but again this rarely happens.   8 
 9 
In 2014, ISPOR established a Good Practices for Outcome Research Task Force for using HSUs 10 
in cost-effectiveness models. This task force report provides recommendations for researchers 11 
identifying, reviewing and synthesising HSUs for use in cost-effectiveness models, analysts that 12 
use the results in cost-effectivesss models, and reviewers that critically appraise the suitability and 13 
validity of the HSUs selected for these studies. The associated ISPOR Health State Utility Good 14 
Practices Task Force Minimum Reporting of Systematic Review of Utilities for Cost-15 
Effectiveness (SpRUCE) Checklist provides criteria to judge the appropriateness of the HSUs 16 
selected for use and is suitable for use across different international settings.  17 
 18 
Keywords: cost-effectiveness, systematic review, health state utility, health related quality of life. 19 
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Identification, Review and Use of Health State Utilities in Cost-Effectiveness Models:  20 
Good Practices for Outcomes Research 21 
 22 
  23 
I. INTRODUCTION 24 
 25 
Cost-effectiveness models that present results in terms of cost per quality adjusted life-year 26 
(QALY) for health technologies are used to inform policy decisions in many parts of the world.  27 
Health state utility (HSU) data are required to calculate QALYs.  HSUs describe the value of a 28 
health state on a 0-1 scale, where one represents full health, zero represents states judged to be as 29 
bad as being dead and negative values represent states judged to be worse than dead.  The 30 
preference values are usually obtained by elicitation techniques like standard gamble (SG) or 31 
time-trade-off (TTO) from a sample of the general population (though patient populations may be 32 
used). 33 
 34 
If HSUs are not available from trials, and it is not feasible to conduct a study to collect this 35 
evidence, they are often sourced from the literature.  This is problematic because analysts 36 
frequently cite dated evidence used in previous evaluations without undertaking basic quality 37 
checks of the data in the original source material, e.g., the relevance of the patient population, 38 
utility measure, elicitation method or sources of the preference weights.  Furthermore, systematic 39 
reviews of the literature are rarely undertaken for HSUs, and current reporting standards are often 40 
poor (1).  41 
 42 
Different samples, estimation methods and preference weights can result in different HSUs for the 43 
same health state (2,3,4).  Selecting evidence in an ad hoc manner will result in unjustifiable 44 
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conclusions and raise WKHVXVSLFLRQRIµFKHUU\SLFNLQJ¶For consistency within a model, it is 45 
preferable that all health states are informed by evidence obtained using the same preference-46 
based measure and preference weights, although this may not always be possible.   47 
 48 
Where there are multiple appropriate HSUs for a particular health state or where it is not possible 49 
to identify all HSUs from the same measure, there may be a case for synthesising the data.  50 
Furthermore, it is likely that even the most appropriate HSUs may not exactly match the 51 
definitions of the health states within the model.  Consequently, analysts frequently µDGMXVW¶WKH52 
data in some way to account for age, concurrent clinical events or adverse effects of treatment (5).  53 
 54 
To address these issues, this report provides recommendations on the identification, critical 55 
appraisal and synthesis of HSUs from the literature, minimum reporting standards and the use of 56 
this evidence in cost-effectiveness models. It is the third ISPOR Health State Utility Good 57 
Practices Task Force Report.  For detailed information on primary data collection and the 58 
derivation of mapping functions, please see the other reports (6,7). 59 
 60 
II. SEARCH METHODS FOR IDENTIFYING HEALTH STATE UTILITIES IN 61 
THE LITERATURE  62 
 63 
HSUs are available from a wide range of study designs, including randomised controlled trials, 64 
observational studies and economic evaluations (8). Systematic review guidance on how to search 65 
for studies systematically and transparently is useful for informing generic considerations, e.g., 66 
which databases to search and how to devise search strategies (9).  However, searches for HSUs 67 
for models need to account for several requirements of the modelling process. These include: the 68 
iterative nature of model development, the scope of HSUs required, and judgments on the 69 
extensiveness of searches (10).   70 
 71 
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Iterative searching 72 
Searches for HSUs are rarely a discrete, single activity at the outset of model development as final 73 
requirements may not be fully defined at that time.  They are generally an iterative process 74 
involving multiple searches to identify the full scope of evidence required.  75 
 76 
Initial scoping searches can inform early conceptualisations of the model and these early versions 77 
of the model will clarify specific information needs for further searches.  For example, 78 
exploratory analysis may show that the model results are sensitive to certain HSUs, and 79 
insensitive to others.  Future searches can then focus on the HSUs that influence the results. 80 
Consequently, interaction between the modeller and the information specialist is required to 81 
inform the evolving direction and scope of the iterative search activities. 82 
 83 
Iterative searching can combine the more traditional in-depth search techniques with techniques to 84 
improve efficiency in order to explore a wide cross-section of potentially relevant evidence.   85 
Techniques to increase the efficiency of searching include initial, focussed searching to maximise 86 
the relevance of the search retrieval, e.g., by searching for relevant terms in the title only, 87 
followed by broader iterations of searching, e.g., by extending the search to abstracts.  Guidance 88 
on iterative search techniques has been published by the NICE Decision Support Unit (11). 89 
 90 
Scope of searches 91 
The scope of evidence required should account for all health states and all aspects of treatment 92 
and management that might have an impact on HRQoL or might be affected by the intervention 93 
and comparators under consideration within the model.  As such, multiple keyword search 94 
strategies may be required. For example, a cost-effectiveness model for the management of 95 
hypercholesterolaemia required HSUs for downstream events including stable and unstable 96 
angina, stroke and myocardial infarction (12). 97 
 98 
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A search approach that takes a systematic account of the full range of evidence requirements 99 
arising from the modelling framework is an important divergence from standard systematic 100 
review search methods.  The latter are commonly associated with reviews of clinical effectiveness 101 
that focus on capturing evidence using a single search strategy defined by the population and 102 
intervention elements of the structured PICO (population, intervention, comparator, outcomes).  A 103 
systematic account of the range of evidence to be retrieved should be determined by the 104 
requirements of the decision problem (See Figure 1).  Factors to consider when identifying 105 
possible search criteria are provided in Table 1. 106 
 107 
Table 1: Factors to consider when defining search criteria 108 
Essential factors required to define search criteria 
x Health state descriptions within the model  
x Treatment effects of interventions and comparators of interest (including utility gains 
from treatment benefits and utility losses through adverse effects) 
x Treatment effects and management at all stages of the clinical pathway included in the 
model  
x Carer health state utilities 
x Comorbidities 
x Concurrent clinical events/sequelae 
x General population norms 
x Moderator variables that might affect quality of life, e.g., method of administration, 
treatment setting 
Additional factors that may be relevant: 
x µMapping IXQFWLRQV¶IRUHVWLPDWLQJSUHIHUHQFH-based utilities from other HRQoL 
measures or clinical variables (See mapping section in this report.)  
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x The context within which the model will be used, e.g., geographical location or 
reimbursement agency criteria (23) [Rowen DL, Azzabi Zouraq I, Chevrou-Severac H 
& van Hout B (2017) International regulations and recommendations for utility data for 
health technology assessment. PharmacoEconomics, 35(Suppl 1), 11-19.] 
 109 
 110 
Extent of searching 111 
Exhaustive searching is a fundamental methodological precept of systematic reviews. While this 112 
is recommended practice for parameters of treatment effect (13), there is consensus that 113 
exhaustive searching for every model parameter is not an efficient use of resources (14,15).   114 
 115 
To the extent that it is possible, it is important that the search process is 1) systematic and 2) 116 
explicitly stated to demonstrate that evidence has not EHHQLGHQWLILHGµserendipitously, 117 
opportunistically or preferentially.¶ (11)  Recommendations to achieve a minimum level of 118 
searching across all key model parameters, have been published (16) . These recommendations 119 
stress the need to undertake further searching if required or to provide justification if the 120 
minimum search level identified sufficient evidence. 121 
 122 
Currently, there is no empirical definition of sufficient evidence or sufficient searching.  In the 123 
absence of such definitions, the search objective VKRXOGEHµto identify the breadth of information 124 
needs relevant to a model and sufficient information such that efforts to identify further evidence 125 
would add nothing to the analysis¶ (17). This concept is useful in informing heuristic judgments 126 
as to when to stop searching (18).  Sufficiency checks include: 127 
x Sensitivity analysis to understand the impact of HSUs on model outputs. Search activities 128 
can prioritise HSUs to which outputs are most sensitive. 129 
x The availability of evidence. Extensive searching is not of value where there is minimal or 130 
a lack of appropriate evidence. 131 
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 132 
Search tools 133 
Guidance on how to search for studies for inclusion in systematic reviews of HSUs provide details 134 
on how to search general biomedical databases, such as Medline and specialist databases 135 
(including the TUFTS Database, ScHARRHUD and the HERC Mapping Database (Health 136 
Economics Research Centre, Oxford, UK)) (19). The ISSG (InterTASC Information Specialist 137 
Subgroup) Search Filter Resource (20) provides HSU filters for use with databases such as 138 
Medline (21).  Further guidance on searching is useful in adapting the search process for HSU 139 
systematic reviews to the specific requirements of cost-effectiveness models (11,16). 140 
 141 
REVIEWING PROCESS OF HEALTH STATE UTILITIES  142 
After completing the iterative literature searches and identifying articles that satisfy the inclusion 143 
criteria, some general recommendations can be considered as a starting point to review the 144 
articles.  Initial considerations include the quality and appropriateness of the data.  Depending on 145 
the target reimbursement agency or audience, additional considerations may include the choice of 146 
preference-based measure and/or source of preference weights, the study setting, and whether to 147 
allow evidence from another measure (Figure 1).   148 
 149 
Quality of the data  150 
Studies should be reviewed for evidence of methodological flaws or bias and limitations using the 151 
following as a minimum: 152 
a. Precision of the evidence: The precision of the data will be reflected in the variance, which 153 
is related to sample size.   154 
b. Response rate: The generalisability and validity of the evidence may be compromised if a 155 
substantial proportion of eligible subjects declined to participate.  156 
c. Loss to follow-up and missing data: The rates of losses to follow-up may compromise the 157 
representativeness of the final sample.  The levels of missing data, whether these can be 158 
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considered as missing at random, and how researchers deal with these, must be reported.  159 
This is particularly important in longitudinal evidence where data are assessed at interim 160 
points over time. 161 
 162 
Appropriateness of the data  163 
Patient characteristics/health state definitions 164 
First and foremost, the population of the study must be comparable to the population modeled.  165 
0RGHO¶V health states are often defined in terms of objective clinical measures.  It may be 166 
necessary to have HSUs for health states defined by stage or severity of disease, comorbidities, 167 
age, gender, ethnicity, adverse events, or complications and sequelae.  In chronic conditions 168 
FKDUDFWHULVHGE\V\PSWRPH[DFHUEDWLRQVHJ&URKQ¶VGLVHDVHRUJRXW; or multiple discrete 169 
events, e.g., a transient ischemic attack or asthma, HSUs can fluctuate over time.  Thus, it is 170 
important to consider timing of data collection, e.g., how close in time was the event and data 171 
collection point, and is this likely to result in statistically different HSUs?  The use of any 172 
medications that are likely to have an independent effect on HSUs (either detrimental or 173 
beneficial) should be considered. 174 
 175 
Preference-based measure and elicitation method 176 
It is common practice for HSUs to be based on patients completing an HRQoL measure with the 177 
general public providing weights for the measure using techniques, such as TTO or SG (22).  In 178 
general, when using HTA for decision-making on reimbursement or new technologies, societal 179 
weights are preferred over patientV¶ (23).  There are deviations from this and some decision 180 
makers prefer the weights from patients rather than the public e.g., the Dental and Pharmaceutical 181 
Benefits Agency in Sweden.  Sometimes it is necessary to use proxy assessment, sometimes 182 
condition-specific measures are preferred to generic,  and some agencies prefer all HSUs from the 183 
same measure, e.g., NICE and the Dutch National Health Care Institute (23).  184 
 185 
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An important aspect is the extent to which the measure is valid or appropriate for the condition.  A 186 
measure should be sensitive to changes in the domains of health likely to be affected by the 187 
condition.  For example, when evaluating interventions for mental conditions affecting self-188 
esteem or social relationships, it is important that the measure can capture changes in these (24).  189 
In some conditions, certain measures have been shown to be insensitive, e.g., EQ-5D in hearing 190 
loss and some visual disorders (25).       191 
 192 
Consistency of evidence 193 
Using a single measure (and preference-weights) for all HSUs within a model removes variance 194 
due to different valuation methods, populations, etc.  However, it is not always possible to 195 
identify all HSUs from a common measure.  There may be a trade-off between the desirable 196 
characteristics of the HSUs or a specific measure, and coverage of the most important health 197 
states in the model in terms of effect on the incremental cost-effectiveness ratio (ICER).   198 
 199 
The final evidence XVHGPD\EHVHOHFWHGE\WUDGLQJRIIµLGHDO¶FKDUDFWHULVWLFVsee Figure 1) that 200 
are likely to differ across models.  Where all HSUs needed are not available from a common 201 
source, consistency of the measure is a priority, subject to the robustness of the data.  In some 202 
instances, the exact patient characteristics and timing of the data collection may outweigh the 203 
specific measure.  The final selection should be transparently reported and justified by the use of 204 
pre-determined criteria.  Any suitable alternatives should be considered in sensitivity analysis.   205 
 206 
III. SYNTHESIS OF HEALTH STATE UTILITIES 207 
 208 
Why undertake a synthesis? 209 
There are often multiple published HSUs for a given health state.  To use one source per state is 210 
not making best use of the available evidence. The aim of synthesis is to generate a more accurate 211 
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estimate of the mean HSU and the associated uncertainty, and to improve the generalisability of 212 
findings.   213 
 214 
When should a synthesis be undertaken? 215 
Before undertaking a formal synthesis of HSUs, it is important to consider whether there are 216 
enough HSUs and whether the studies are sufficiently homogenous for the aggregation to be 217 
meaningful.  For meta-regression of effectiveness, a minimum of four studies in a categorical 218 
subgroup variable has been suggested (26), while more are required to conduct significance 219 
testing.  220 
 221 
Heterogeneity can be a major problem.  Peasgood et al. (2015) identified considerable variability 222 
in HSUs arising from differences between: measures (EQ-5D vs. SF-6D), valuation method, 223 
(TTO vs. SG), the types of anchors used, the country of the valuation, and who provided the 224 
preference weights (patient vs. general population) (27).  The large number of sources of variation 225 
can imply that any formal synthesis is not meaningful particularly if they exceed the number of 226 
HSUs used.   227 
 228 
:KDW¶VWKHUROHRIPDSSLQJ in evidence synthesis? 229 
Mapping can expand the number of relevant HSUs available for synthesis in two situations.  The 230 
first is studies using health or HRQoL measures that do not generate preference-based HSUs.   231 
The second is where HSUs are obtained using different preference-based measures, or different 232 
valuation techniques.      233 
 234 
In both cases, there may be functions that map or cross-walk from one measure onto a generic 235 
preference-based measure, e.g., EQ-5D (28).  However, mapping functions increase uncertainty 236 
and can produce systematic error in estimation (6).  Mapping functions are generally used in 237 
situations where patient level data is available, although it is possible to map from mean HSUs.    238 
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 239 
Methods of synthesis 240 
Syntheses aim to estimate the absolute or relative impact of each health state on the corresponding 241 
HSU.  The methods for synthesis are at an early stage of evolution.  Therefore, we are limited in 242 
the recommendations that we can currently make.  There are two broad approaches. One involves 243 
applying strict eligibility criteria to studies included in the analysis in order to reduce 244 
heterogeneity, such as limiting HSUs to those obtained from the same measure and specific sub-245 
groups, e.g., mild, moderate or severe depression.   246 
 247 
This is appropriate where there are sufficient numbers of HSUs meeting the criteria.  For example, 248 
Peasgood, et al. (2015) excluded all non EQ-5D evidence (to meet NICE¶Vpreferred measure) and 249 
combined nine studies to estimate mean HSUs (27).  Considerable unexplained heterogeneity 250 
remained despite using the same measure, which raised concerns about the relevance of the 251 
estimates for use in cost-effectiveness models.  252 
 253 
When there are not enough studies using the same method on a sufficiently homogenous 254 
population, more sophisticated methods are needed. The second approach attempts to explicitly 255 
model the impact of heterogeneity on the HSUs using meta-regression.  For example, Bremner 256 
and colleagues (2007) estimated a linear mixed-effects model in prostate cancer to estimate 257 
coefficients for disease stage, symptoms, severity, and valuation methods (29).  The authors 258 
acknowledged problems with over-predicting HSUs at the lower end and predicting HSUs greater 259 
than one.   260 
 261 
A study in colorectal cancer used a similar linear mixed logit model and compared it to a 262 
Bayesian logit model-based model.  They found the latter gave a better fit, although the 263 
coefficients need transforming for use in cost-effectiveness (30).  In both studies, considerable 264 
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heterogeneity remained, partly because the models were limited by the variables published in the 265 
studies, and partly because the authors did not have access to individual level data.   266 
 267 
Meta-regression methods require a lot of data to control for the different sources of variation 268 
between studies.  Ten studies per covariate has been suggested in the literature, but this may not 269 
be realistic for many indications (31).  Methodological research is needed into methods of meta-270 
regression when synthesising HSUs and when they are appropriate.  271 
 272 
Another under-explored source of variation is that evidence differs by country of patient 273 
recruitment.  This may be due to differences in patient characteristics that can be controlled for in 274 
meta-regression.  It can also be due to differences in country specific preference-weights for 275 
measures like EQ-5D.  However, oftentimes the preference-weights in one country are used in 276 
another, e.g., UK EQ-5D preference-weights are used in submissions to the US Institute for 277 
Clinical and Economic Review.  278 
 279 
There is no standard way to re-weight from published values, and this can only be done with 280 
access to individual level data.  In addition, there may be a country-specific effect from the 281 
general health of patients or the impact of the healthcare system more generally.  The importance 282 
of these different sources of variation and how to deal with them needs to be further explored.   283 
 284 
Current experience using formal synthesis methods is limited for HSUs.  For pragmatic reasons, 285 
many of the more complex techniques commonly used in the clinical efficacy literature may have 286 
little role when synthesising HSUs due to the limited number of studies and the high degree of 287 
heterogeneity in the valuation methods and patient populations.  However, with a growing 288 
literature, there will be increasing opportunities to use meta-analysis with HSUs.   289 
 290 
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IV. MINIMUM REPORTING STANDARDS FOR LITERATURE REVIEWS AND 291 
MODELLING REPORTS  292 
 293 
We recognize the challenge of extensive documentation when multiple literature reviews are 294 
necessary and models encompass multiple conditions/co-morbidities.  However, the fundamental 295 
tenets of systematic reviews, such as systematic search, critical appraisal and transparency of 296 
reporting, as described in the ISPOR CHEERS report, are still critical to the success of the review 297 
(32).  The iterative nature of the search and review process is outlined in Figure 1.  298 
 299 
 300 
In Table 2, we outline criteria to support minimum reporting standards for the systematic review 301 
of HSUs for cost-effectiveness - the ISPOR HSU Good Practices Task Force Minimum Reporting 302 
Standards of Systematic Review of Utilities for Cost-Effectiveness (SpRUCE) Checklist (ISPOR 303 
SpRUCE Checklist).  These criteria were designed to help reviewers identify if HSU selection for 304 
the model was transparent and appropriate.  The checklist has five sections that refer to the search 305 
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strategy, the review process, the data extracted from each study, the rationale for the final HSU, 306 
and their use in the model. While the ISPOR SpRUCE Checklist provides a minimum set of 307 
reporting standards for HSUs in models, a greater level of detail is likely needed to proceed to 308 
peer-reviewed publication of a systematic review (33).  309 
  310 
Table 2:   ISPOR HSU Good Practices Task Force Minimum Reporting Standards of 311 
Systematic Review of Utilities for Cost-Effectiveness (ISPOR SpRUCE Checklist) 312 
Criteria Description 
Search Strategy  
Search terms and scope The final search strategy should be adequately 
defined, and appropriate databases included in 
the search.   
Study selection criteria Explicit criteria for study 
identification/inclusion should be described 
and applied, such as patient group of interest, 
relevant age range and stage of 
disease/severity etc. 
Review Process  
Quality check Quality criteria for reviewing studies is 
explicitly stated and applied. 
Assessment of relevance Relevance of HSUs to model and target 
reimbursement agency described.    
Data Extracted (Reporting of variables) 
Population/patient characteristics  Include relevant patient characteristics such as 
age, sex, comorbidities, diagnosis, severity of 
condition.# 
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Measure used to describe the HSUs  Provide the name of the actual measure.  
Preference weights State the technique used to value the health 
state e.g., TTO, SG, and the country.  Provide 
the reference. 
Descriptive statistics of HSUs Include the mean and variance around any 
HSU used in the model. 
Response rates to the measure used* Report if response rates are likely to be a 
threat to validity. 
Loss to follow-up/ missing data* Report loss to follow-up, e.g., 1 year after 
fracture, and missing data especially if they 
may threaten the representativeness of the 
HSUs. 
Original reference The original source for the HSUs should be 
referenced (NOT a previous economic study 
that has used the evidence).   
Selection/estimation of final health state utilities 
Basis for selecting HSUs The rationale for selecting the HSUs used in 
the model should be justified. 
Method used to combine estimates Where HSUs are combined, the analytic 
methods should be described, e.g., meta-
analysis.   
Methods used when applying the health state utilities in model 
Actual HSUs used Report all actual HSUs used in the model 
together with the associated measure. 
Adjustments or assumptions Clearly describe any adjustments or 
assumptions relating to the use of HSUs in the 
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model.  Report both the raw and final values 
used with worked examples, if required to 
clarify the method used to adjust the data. 
*Extract and report if relevant.  
#
 The original primary source should be checked rather than relying on the use of data from a 
similar economic model without checking relevance 
SG: standard gamble; HSU: health state utility; TTO: time trade-off  
 
 313 
Search strategies  314 
Ideally, the search and selection methods used in a systematic review should be described in a 315 
protocol prior to study initiation.  While initial searches may be somewhat cursory, HSUs found 316 
to be important, e.g., through sensitivity analysis, should drive a more comprehensive search 317 
strategy.  Associated reports should specify the terms used in search strategies and the databases 318 
reviewed.  Additional non-standard search strategies, e.g., hand searches, non-peer reviewed 319 
literature or HTA type submissions should be described.   320 
 321 
Review Process 322 
The process for screening and determining the eligibility of studies should be reported together 323 
with the number of reviewers involved and how disputes were resolved.  The iterative search 324 
process and associated inclusion criteria could be summarised in a PRISMA flow diagram (34).  325 
Studies reporting HSUs that met the inclusion criteria, yet were not selected DIWHUWKHµWUDGH-RII¶326 
process, should be listed.  327 
 328 
Data extraction 329 
Upon identification of studies that meet the inclusion criteria, data used to assess the 330 
appropriateness of the HSUs should be extracted and summarized (See Figure 1, Section 2).  For 331 
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modelling reports, data extraction could be limited to those studies that were included as a model 332 
input.   333 
 334 
Elements of the studies providing the HSUs used should be described in the review, such as study 335 
design, e.g. observational or clinical trial, whether it was a clinical study versus patient survey, 336 
and possible study limitations, such as aspects of the design that may promote placebo effects that 337 
can inflate HSUs.  It is important to identify and reference the original source document.  338 
Secondary references are a common issue in reviews of HSUs and modelling reports.  If the 339 
authors of a study have been contacted for clarification or even original data, this should be 340 
documented.   341 
 342 
Selection/estimation of final HSU for model 343 
If a review results in the identification of multiple appropriate HSUs, the following should be 344 
reported: 1) selection - justify the rationale for the selection of the best evidence or 2) estimation - 345 
the methods for combining the evidence should be reported and justified, e.g. meta-analysis, with 346 
tests for heterogeneity that support combining the data.     347 
 348 
V. USING HEALTH STATE UTILITIES IN COST-EFFECTIVENESS MODELS  349 
This section describes issues related to the use of HSUs within cost-effectiveness models and 350 
associated recommendations (See Table 3).  351 
 352 
Discrete health states or discrete event simulation? 353 
In a cost-effectiveness model, HSUs are most commonly assigned to a set of discrete health states 354 
using state transition models.  However, the guidance here extends beyond these.   Modelling 355 
techniques, such as discrete event simulation (DES), can represent the utility effects of all changes 356 
in clinical status through the estimation of HSUs as a function of clinical status. When 357 
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conceptualising a model structure, the number of discrete health states required to capture changes 358 
in clinical status that result in important changes in HSUs should be carefully considered (35).  359 
 360 
There is no consensus on defining important changes in HSUs.  These will likely vary by 361 
condition and utility measure, but the basis on which important changes in HSUs inform the 362 
model structure should be stated explicitly. The required number of discrete health states may lead 363 
to a decision to use DES (36). If a simpler model structure is implemented that does not represent 364 
all potentially important HSUs, the expected effects of such omissions should be examined and 365 
discussed. 366 
 367 
Individual or function-based health state utilities? 368 
HSUs may be estimated individually, analysing the data for each health state separately or a 369 
relevant function may be generated. If both options are available, the choice of data used in the 370 
base case model analysis should be informed by: 1) the relevance of the data (see Section 2), and 371 
2) the reliability of the analyses, e.g., the precision of the mean HSUs and the validity of 372 
estimated functions. Again, the rationale for the final choice should be explicitly stated. 373 
 374 
Comorbidity utility effects and the use of general population norms 375 
HSUs should reflect HRQoL effects associated with the condition of interest, but also any 376 
comorbidities unrelated to that condition. The utility effects of comorbidities are real and should 377 
be represented in HSUs. The consequences of omitting these effects will be greatest in evaluations 378 
of interventions that increase life expectancy because QALY gains will be overestimated if the 379 
utility effects of unrelated comorbidities are not represented (37, 38).  380 
 381 
It is reasonable to assume that mean HSUs represent comorbidity effects at the mean age of the 382 
utility study population. HSUs at younger and older ages should be adjusted to reflect age-related 383 
comorbidity utility effects.  Age-specific HSUs should be estimated using the appropriate 384 
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µPXOWLSOLHU¶)RUH[DPSOHLIDFRQGLWLRQVSHFLILF+68RILVGHULYHGIURPDVWXG\VDPSOH385 
with mean age 70 years, and the general population norm at age 70 years is 0.8, the multiplier is 386 
0.72/0.8 = 0.9.  Age-specific HSUs are then estimated for other ages using the multiplier, e.g., if 387 
the general population norm at age 71 years is 0.79, the age-adjusted condition specific HSU at 388 
age 71 years is 0.79 x 0.9 = 0.711.  If the intervention is prophylactic and suitable data are 389 
available, it is preferable to utilise condition-specific age-adjusted HSUs for the µFRQGLWLRQ-IUHH¶390 
health state.  Evidence suggests these may be lower than general population norms (39). 391 
 392 
Table 3: Methodological recommendations for using health state utilities in cost-393 
effectiveness models 394 
Issue Recommendation 
Individual or 
function-based 
HSUs? 
Decisions should be informed by the relevance of 1) the data, e.g., the 
study population, 2) the utility measure DQGDOLJQPHQWZLWKWKHPRGHO¶V
health states, and 3) the reliability of the reported analyses, e.g., the 
precision of the mean HSUs and the validity of estimated utility functions.  
Comorbidity 
utility effects and 
the use of general 
population norms 
Mean HSUs represent comorbidity utility effects at the mean age of the 
utility study population. Age-specific comorbidity effects should be 
estimated using age-specific population norms.  If the intervention is 
prophylactic and suitable data are available, it is preferable to utilise 
condition-specific age-DGMXVWHG+68VIRUWKHµFRQGLWLRQ-IUHH¶KHDOWKVWDWH 
Treatment-related 
adverse events 
The extent to which the utility effects of adverse events are captured by the 
GDWDXVHGWRHVWLPDWHDPRGHO¶VQRQ-adverse event HSUs should be 
assessed. If adverse event HSUs are required, the range of HSUs to be 
estimated should be informed by their expected impact on cost-
effectiveness. 
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Concurrent 
clinical events 
The multiplicative method should be used to handle the utility effects of 
multiple concurrent clinical events. 
Acute clinical 
event  
In the absence of data collected around the event, plausible HSUs for the 
direct effects of acute events should be multiplied by the expected duration 
of the direct effects to assess the sensitivity of cost-effectiveness to these 
utility effects. 
Sensitivity 
analysis 
One-way and multi-way sensitivity analyses of HSUs should be 
undertaken. The difference method should be used to maintain appropriate 
ordering of HSUs in probabilistic sensitivity analyses. 
 395 
Treatment-related adverse events and concurrent conditions 396 
The need to estimate the disutility associated with adverse event reflects the extent to which this is 397 
already captured in the HSUs used for the PRGHO¶Vhealth states. If individuals experiencing 398 
adverse events were less likely to return utility data, the disutilities of adverse events are likely to 399 
be underestimated. Alternatively, little data may be available on high impact, but uncommon, 400 
adverse events. In these cases, additional literature should be sought to estimate the disutility of 401 
adverse events, noting that the original HSUs may partially reflect adverse event effects.  402 
 403 
The adverse event HSUs to be estimated should be justified with reference to incidence rates in 404 
the different treatment groups, their severity and duration, and the expected sensitivity of the cost-405 
effectiveness results to the adverse event HSUs. A wider range of adverse event HSUs should be 406 
estimated as the expected impact of the HSUs on the cost-effectiveness results increases. The 407 
estimated effects should reflect the expected duration and pathway of the adverse events. 408 
 409 
Individuals may also experience concurrent clinical events related to the condition of interest, e.g., 410 
diabetic patients may experience both cardiovascular disease and retinopathy.  Approaches to 411 
handling the utility effects of multiple concurrent clinical events include: 1) subtracting the sum 412 
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of the estimated utility decrements for overlapping events from baseline HSU (additive); 2) 413 
multiplying the baseline HSU by the product of the ratios of the HSUs for individuals with and 414 
without the clinical events (multiplicative); and 3) the use of the lowest HSU across the clinical 415 
events (minimum) (38).   416 
 417 
A review of 11 studies that used HSUs for single health conditions to estimate HSUs for 418 
concurrent health conditions found the minimum approach overestimated all observed HSUs and 419 
the multiplicative method was generally preferred to the additive method (38). The review noted 420 
the potential value of regression-based predictions of concurrent utility effects, whilst recognising 421 
the need for further research to validate regression approaches. On the basis of the existing 422 
evidence, the multiplicative method (using an appropriate multiplier) is the recommended 423 
approach. 424 
 425 
Acute clinical event utility effects  426 
Acute clinical events, such as asthma exacerbations and bone fractures, may be associated with 427 
large utility decrements due to high levels of pain or discomfort. However, it is rarely the case that 428 
respondents complete utility measures during the time period over which the effects of such acute 429 
events are experienced. The best solution to this problem is to tailor data collection to the events 430 
of interest (7). The impact of omitted utility effects is likely to be greatest for acute events that 431 
occur on a regular basis, such as asthma exacerbations and angina attacks.  The timing of data 432 
collection for HSUs used from the literature should be assessed for appropriateness before used in 433 
the model.  434 
 435 
To assess the sensitivity of the model outputs to acute event utility effects, analysts should 436 
generate plausible HSUs based on the expected clinical effects of the event, e.g., defining 437 
expected dimension of health levels from a multi-attribute utility instrument. The estimated HSU 438 
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can be multiplied by the expected duration of the effects to estimate the QALY loss per acute 439 
event, which can be applied to each occurrence of the event in the cost-effectiveness model. 440 
 441 
Sensitivity analysis 442 
Uncertainty around the mean HSUs (including population norms) should be represented by 443 
parametric probability distributions (40).  Lower and upper confidence limits can be used in 444 
deterministic sensitivity analyses and random samples generated from the distributions for 445 
probabilistic sensitivity analyses (PsA). Uncertainty around HSUs should generally be represented 446 
by a standard beta distribution, which is bounded by 0 and 1. However, alternative lower and 447 
upper limits should be defined if a negative HSU is possible (41).  448 
 449 
One-way sensitivity analyses should be undertaken to identify the HSUs to which the model 450 
results are most sensitive. Relevant multi-way sensitivity analyses include combined analyses of 451 
all HSUs, taking care to select combinations of lower and upper HSUs that move the cost-452 
effectiveness results in the same direction, i.e., all selected HSUs either improve or worsen cost-453 
effectiveness.  454 
 455 
Ordered HSUs refer to pairs of HSUs in which there is an absolute belief that the true expected 456 
HSU for one state is higher than the true expected HSU for another state, e.g., a pre-diabetes HSU 457 
is higher than a diabetes HSU.  In PsA, inconsistent HSUs can be sampled if there are overlapping 458 
probability distributions for ordered HSUs, e.g., a higher value could be sampled for the diabetes 459 
than for the pre-diabetes.  460 
 461 
To avoid sampling inconsistent HSUs, the difference method should be used (42). This involves 462 
generating a probability distribution of the difference in the HSUs of two ordered parameters. In 463 
PsA, one of the ordered parameters is sampled, and the difference between the two HSUs is then 464 
added to the sampled value to generate the second HSU. 465 
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 466 
CONCLUSION  467 
This report provides good practice guidance when identifying, reviewing and synthesising HSUs 468 
from the literature and using HSUs in cost-effectiveness models. Historically, analysts have paid 469 
insufficient attention to this parameter, often simply taking evidence used in previous models or 470 
those from a known source with no transparency or justification of choice.  While the time and 471 
resources available for populating cost-effectiveness models will always be limited, the HSUs can 472 
be just as important as other parameters in models. 473 
 474 
It is not always feasible or necessary to undertake comprehensive literature searches, but it is 475 
essential to report the search methods and the criteria used to review studies transparently.  The 476 
processes for searching and reviewing are iterative as the scope of a search will depend on the 477 
literature available. It may be necessary to relax the search terms and inclusion criteria to allow 478 
more measures to identify appropriate evidence. 479 
 480 
Any review criteria should be stated a priori as there are often trade-off decisions between 481 
criteria.  Where all HSUs needed are not available from a common source, consistency of the 482 
measure is a priority, subject to the robustness of the data.  Finally, searching and reviewing 483 
should be undertaken as part of the model development, since the results can influence the 484 
structure of the model and the sensitivity of the ICER can inform prioritisation of searches to the 485 
HSUs that are influential.   486 
 487 
Due to the increase in the evidence base reporting HSUs, there may be more than one relevant 488 
HSU for each health state.  Analysts should consider meta-analyses to generate more 489 
representative estimates (as for any other model parameter) or meta-regression to utilise the full 490 
range of evidence from heterogeneous studies. 491 
 492 
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:KLOHWKHOLWHUDWXUHLVJURZLQJWKHUHDUHRIWHQµJDSV¶LQWKHHYLGHQFH$QDO\VWVIUHTXHQWO\DGMXVW493 
HSUs to account for adverse events, comorbidities and age.  Analysts should report any issues 494 
with the evidence sources, the methods used to adjust the data, and the actual HSUs used in the 495 
model explicitly and transparently to enable readers to review the implications of the decisions 496 
made.  The uncertainty in the HSUs should be captured appropriately.   497 
 498 
These good practice task force recommendations and the ISPOR SpRUCE Checklist offer a 499 
structured and transparent basis for identifying and reporting the HSUs used in a cost-500 
effectiveness model. 501 
  502 
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